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Despite recent advances, the diagnosis and management of heart failure evades the cli-
nicians. The etiology of congestive heart failure (CHF) in the Indian scenario comprises of
coronary artery disease, diabetes mellitus and hypertension. With better insights into the
pathophysiology of CHF, biomarkers have evolved rapidly and received diagnostic and
prognostic value. In CHF biomarkers prove as measures of the extent of pathophysiological
derangement; examples include biomarkers of myocyte necrosis, myocardial remodeling,
neurohormonal activation, etc. In CHF biomarkers act as indicators for the presence,
degree of severity and prognosis of the disease, they may be employed in combination with
the present conventional clinical assessments. These make the biomarkers feasible
options against the present expensive measurements and may provide clinical benefits.
Copyright ª 2014, Cardiological Society of India. All rights reserved.1. Introduction
A variety of circulating molecules referred to as biomarkers
have been introduced in clinical cardiovascular research,
including heart failure (HF) research, because of basic science
discoveries and technological progress in the last decade.
Research papers related to biomarker research in HF have
been exponentially circulating over the last decade (Fig. 1).tide; HF, heart failure.
262.
I. Satyamurthy).
2014, Cardiological SocietThe dissemination of knowledge about biomarkers in HF
clinical practice, however, is limited mostly to diagnostic uses
of B-type natriuretic peptide (BNP) or its precursor fragment,
N-terminal prohormone of brain natriuretic peptide (NT-
proBNP). Biomarkers in circulation include a variety of mole-
cules that range from traditional protein-based markers to
newer markers and micro RNAs. Protein markers in circula-
tion typically comprise hormones and prohormones with
vasoactive properties which include natriuretic peptidesy of India. All rights reserved.
Fig. 1 e “Biomarker” and “Heart failure” articles published
from 2001 to 2011.1
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 7 3e8 274(NPs), endothelin, mid-regional pro-adrenomedullin, and
C-terminal provasopressin (copeptin); structural proteins
which include troponins; and various proteinswith enzymatic
activities which include myeloperoxidase and galectin-3. The
current status of biomarker application for diagnosis and
management of HF is confusing. A general framework pro-
posed for cardiovascular biomarkers exists and this frame-
work can help to identify the challenges of biomarker
adoption for risk prediction, disease management, and treat-
ment selection in HF.12. Pathogenesis of heart failure
Heart failure is amulti-factorial diseasewith causes varying in
different parts of the world. Minimum 50% of the patients
with HF have a reduced ejection fraction (REF) i.e. HF-REF
which is the most understood type of HF in terms of the dis-
ease pathophysiology and treatment. In approximately two-
thirds of cases of systolic HF, coronary artery disease (CAD)
is the cause, although hypertension and diabetes are probable
contributing factors in many cases. Other factors responsible
for HF include a history of viral infections (known or un-
known), chemotherapy (e.g., doxorubicin or trastuzumab),
alcohol abuse, and ‘idiopathic’ dilated cardiomyopathy (in
some of the cases the cause may be genetic).2
The epidemiological profile in HF with preserved ejection
fraction (HF-PEF) seems to be different from epidemiological
and etiological profile in HF-REF. The patient with HF-PEF
is older, and more often female and obese than those with
HF-REF. They are less likely to have coronary heart disease
and more likely to have hypertension and atrial fibrillation
(AF). As compared to patients with HF-REF, the patients with
HF-PEF have better prognosis.2
When LV systolic function is reduced, the maladaptive
changes occur in surviving myocytes and in extracellular
matrix after myocardial injury (e.g., myocardial infarction)
that lead to pathological ‘remodeling’ of the ventricle with
dilatation and impaired contractility, onemeasure of which is
a reduced EF. In cases of unmanaged systolic dysfunction,
there is progressive worsening of these changes over time
with an increased enlargement of the left ventricle and
declining EF, the patient may be symptomless initially.2This progression occurs due to two mechanisms, of which
the first one is occurrence of further events leading to addi-
tional myocyte death (e.g., recurrent myocardial infarction).
The second mechanism is the systemic responses that are
induced by the decline in systolic function, particularly
neurohumoral activation. The renin-angiotensin-aldosterone
system and sympathetic nervous system are the two key
neurohumoral systems activated in HF. These systemic re-
sponses cause further myocardial injury; leading to detri-
mental effects on the blood vessels, kidneys, muscles, lungs,
and liver; and form a pathophysiological ‘vicious cycle’,
responsible for various clinical features of the HF syndrome,
including myocardial electrical instability.2
The basis of much of the effective treatment of HF is
interruption of these two key processes. The aforementioned
changes are associated with the clinical development of
symptoms and worsening of these over time. This results in
reduced quality of life, degrading functional capacity, recur-
ring frank decompensation episodes leading to hospitaliza-
tion and premature death, commonly as a result of
arrhythmias or pump failure. These patients have a limited
cardiac reserve which also is dependent on atrial contraction,
synchronized contraction of atriaeventricles and a normal
interaction between the right and left ventricles.2
Acute decompensation can result from intercurrent events
affecting any of these [e.g., the development of AF or con-
duction abnormalities, such as left bundle branch block
(LBBB)] or imposing an additional hemodynamic load on the
failing heart (e.g., anemia). The outcome of HF patients can be
improved with effective treatment, with a relative reduction
of 30e50% in hospitalization in recent years, and small but
significant decrease in mortality.23. Incidence of heart failure: Indian scenario
Framingham study was a landmark study indicating that the
incidence of CHF increases with age and is higher inmen than
in women. Although data on incidence of HF from India are
scarce, a 2013 study from India was conducted to measure the
burden of disease. This studywas conducted in southern India
and it was found that 258 males (82%) and 137 females (73%)
had left ventricular HF predominantly, as compared to
biventricular HF. In this study, an interesting feature noted
was that multi-factorial cause was the commonest etiology
for CHF with CAD being the single most common factor
contributing to 66% of cases of HF. Out of all cases of CAD in
this study, 66% cases of HF were men and 34% were women.3
Coronary artery disease in the Framingham study, accounted
for only 46% of cases of HF inmen and 27% of chronic HF cases
in women. Following CAD, hypertension was the leading
factor accounting for 65.6% of cases in this study, while 45.8%
of the population was diabetic. They are, however, not
mutually exclusive. In the Indian study, it was also found that
myocardial infarction in siblings was a significant risk factor.
69% of the patients in the present study had hypertension;
among them 61% were males and 39% were females. There
were 310 (62%) males and 190 (38%) females. The highest
incidence of HF was observed between 50 and 70 years in both
males and females. The researchers from the Indian study
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hypertension and diabetes mellitus, accounting for 23.4% of
the cases. The single commonest etiology for HF was CAD.3Fig. 2 e The processing cascade of natriuretic peptides.64. Multiple biomarkers used in heart
failure e clinical implications
Heart failure progression is complex and is driven by various
biological processes that include inflammation, oxidative
stress, neurohormonal activation, vascular remodeling,
myocyte injury, and renal impairment. Interest is increasing
in the measurement of a diverse biomarker profile, reflective
of the underlying biology of HF, in order to risk stratify pa-
tients and provide a better understanding of the underlying
pathophysiology. A recent study attempted to evaluate the
predictive utility of 8 biomarkers, each reflective of varied
biological pathways in HF: troponin I (TnI) (myocyte injury),
high-sensitivity C-reactive protein (hsCRP) (inflammation), B-
type natriuretic peptide (BNP) (neurohormonal activation),
uric acid and myeloperoxidase (MPO) (oxidative stress), solu-
ble toll-like receptor-2 (ST2) (myocyte stress), creatinine (renal
function) and soluble fms-like tyrosine kinase receptor-1 (sFlt-
1) (vascular remodeling), in a multicenter cohort of 1513
ambulatory chronic HF patients.4
The researchers hypothesized that a biomarker score
summarizing the activity of multiple pathways implicated in
HF would improve the ability to classify risk of adverse out-
comes for ventricular assist device placement, cardiac trans-
plantation, or death compared with a validated clinical risk
prediction algorithm, the Seattle Heart Failure Model (SHFM).4
A median follow up was done at 2.5 years and it was found
that there were 317 outcomes: 187 patients died; 99 were
transplanted; and 31 had a VAD placed. The patients in the
highest tertile of the multi-marker score had a 13.7-fold
increased risk of adverse outcomes compared with the
lowest tertile. The results from this study were in congruence
to the Braunwald’s hypothesis in 2008 that multiple bio-
markers in combination, when classified into categories based
on their pathophysiologic effects in HF, would provide a
valuable means for risk stratification. A multi-marker score of
biomarkers, reflective of diverse biological axes, is a strong
predictor of risk and has significantly improved the prediction
of outcomes compared with the most commonly used clinical
risk score in HF, the SHFM.4
The patients who were in the highest multi-marker tertile
had around 14-fold unadjusted risk of death, transplant, or
VAD placement compared with the lowest tertile. This risk
remained nearly 7-fold after adjustment for the SHFM. A
substantial ability to discriminate individual patient risk at 1
year was shown by the multi-marker score that was again
superior to the SHFM. Multi-marker score in addition to the
SHFM appropriately reclassified a large proportion (24.1%) of
patients as higher risk.4
From these findings, it is evident that multiple biomarkers
are useful as a part of an algorithm for assessing prognosis in
HF. A score derived from multiple biomarkers, integrating
diverse biological pathways in ambulatory chronic HF pa-
tients, substantially improves prediction of adverse events
beyond current metrics.45. Natriuretic peptides in heart failure e
relation to clinical outcomes (evidence review)
Over the last decade introduction of BNP started a new para-
digm in the use of biomarkers in the evaluation and man-
agement of HF. B-type natriuretic peptide and NT-proBNP
belong to a family (Fig. 2) of naturally occurring hormones
known as NPs. High plasma BNP and NT-proBNP levels, syn-
thesized in the cardiac ventricles, are very specific for elevated
filling pressures in the patients with left ventricular dysfunc-
tion, and can provide relatively reliable diagnostic and prog-
nostic information.55.1. Evidence review
Plasma BNP and NT-proBNP have been studied mostly as
diagnostic tools in HF patients. Two prospective multicenter
clinical trials established the role of BNP and NT-proBNP
testing in the initial evaluation of the HF patients.5
In the multicenter Breathing Not Properly Study, using
plasma BNP level of 100 pg/mL as “cut off” gave a sensitivity of
90%, specificity of 76% and a diagnostic accuracy of 81%which
was superior to clinical assessment alone in a series of 1586
patients presented to the emergency department (ED) with
acute dyspnea.5 Randomized controlled trials comparing a
diagnostic strategy involving plasma BNP testing versus clin-
ical assessment alone, plasma BNP testing in the ED improved
the diagnosis and treatment of patients with acute dyspnea
and hence, reduced the time to discharge and the total
expenditure of treatment.5
Angurana et al7 measured BNP in 72 patients of HF with
dyspnea. B-type natriuretic peptide helped to distinguish
dyspnea of cardiac origin from non-cardiac causes. The mean
BNP concentration in patients with CHF (n ¼ 44) was found
significantly higher than in patients without CHF
(399 þ 289.2 pg/ml versus 84.9 þ 42.4 pg/ml) (p < 0. 001). Uni-
variate analysis of plasma BNP level at different cut off levels
revealed that a value of 175 pg/ml had a sensitivity of 81.8%,
specificity of 96.4%, and accuracy of 87.5% for differentiating
CHF from lung disease. Congestive heart failure could be
predicted better by BNPmeasurements that added significant,
independent explanatory power to other conventionally used
clinical variables. The study suggested that rapid measure-
ment of BNP could be a sensitive and specific test for
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 7 3e8 276differentiating the patients with HF from those without, in an
urgent care setting. Another study conducted by Krishna et al
included monitoring of the BNP levels after coronary stenting
in 100 patients suffering from acute coronary syndrome and
noted a significant rise in BNP levels post stenting (Table 1).5
Recent ACS, angiographic thrombus, raised basal troponin,
and presence of LV dysfunction were all associated with high
baseline as well as post PCI BNP levels. Elevated BNP levels
predicted recent ACS more accurately; in patients with
chronic stable angina the BNP levels increased after PCI.55.2. BNP guided therapy versus clinically guided therapy
Randomized controlled trials were reviewed to produce a
recommendation on the use of NPs in the monitoring of HF
patients. The aim of the comparison was to review the
emergence of new studies on the use of NPs in monitoring
patients with HF. Three randomized trials compared BNP
guided therapy to clinically guided therapy (Table 2).55.3. NT-proBNP e relation to clinical outcome
B-type natriuretic peptide is a member of a family comprising
4 NPs in human that share a common 17-peptide ring struc-
ture.7 Before its activation, BNP is stored as a 108eamino acid
polypeptide precursor, proBNP, in secretory granules in both
ventricles and, to a lesser extent, in the atria. After proBNP is
secreted in response to volume overload and resulting
myocardial stretch, it is cleaved to the 76-peptide, biologically
inert N-terminal fragment NT-proBNP and the 32-peptide,
biologically active hormone BNP. Natriuretic peptide receptors
and plasma end peptidases actively clear BNP from the cir-
culation; the plasma half-life is thus short, approximately
20 min. No receptor-mediated clearance of NT-proBNP is
known to occur, and NT-proBNP has a correspondingly pro-
longed half-life of 60e120 min. Thus, plasma NT-proBNP
levels tend to be 3e5 times higher than BNP levels. B-type
natriuretic peptide and NT-proBNP are generally accepted to
be useful for the diagnostic evaluation of the patients with
acute dyspnea. Elevated BNP orNT-proBNP levels is associated
with increased cardiovascular risk as shown by a recentmeta-
analysis analyzing data from 40 long term prospective studies
involving a total of 10,625 incident cardiovascular outcomes
and 87,474 participants.115.4. Interpretation and differential diagnosis of elevated
natriuretic peptide levels
Elevated concentrations of BNP or NT-proBNP are powerfully
associated with the presence of HF; however, neither is 100%Table 1 e B-type natriuretic peptide levels in post PCI
patients.5
Pre PCI Post PCI
Patients with baseline
BNP levels>100 pg/ml
45% of patients with BNP >100 pg/ml
Patients with baseline
BNP levels<100 pg/ml
20% of patients with BNP >100 pg/mldiagnostic for HF. The BNP as well as NT-proBNP levels may
increase in different other disease states, and individual pa-
tient factorsmay influence results. Among the spectrum of HF
syndromes, HF-PEF and systolic dysfunction may raise BNP or
NT-proBNP levels; HF-PEF fractionmay express lower levels of
both peptides in comparison to HF due to systolic dysfunction.
In addition, other relevant cardiac diagnoses, including right
ventricular failure (due to primary cardiac pathology, or sec-
ondary to pulmonary embolism or pulmonary hypertension),
valvular heart disease, and arrhythmias such as atrial fibril-
lation may cause elevation of BNP or NT-proBNP.12
Apart from cardiovascular variables, NP concentrations are
influenced by renal dysfunction and advancing age that may
generate higher values without overt HF; obesity on the other
hand may result in unexpectedly lower NP concentrations,
even in those with HF. To troubleshoot complex situations
such as renal disease, adjustment in cut off points may help
(Table 3).12
Another important situation is the patient with a gray zone
BNP or NT-proBNP value. Approximately, 20% of the patients
with acute dyspnea have BNP or NT-proBNP levels that are
above the cut off point to exclude HF but too low to definitively
identify it. Knowledge of the differential diagnosis of non-HF
elevation of NP, as well as interpretation of the BNP (Fig. 3)
or NT-proBNP (Fig. 4) value in the context of a clinical
assessment is essential; gray zone values are not without
prognosticmeaning, however, and should be approachedwith
caution.13
In the patients with significant renal failure (estimated
glomerular filtration rate, 60 mL/min/1.73 m2) and body mass
index 35 kg/m2 different decision limits must be used (see
text).
Different decision limits must be used (see text).6. BNP levels in renal impairment, obesity
and gray zones
6.1. Renal impairment
There is a high coincidence rate of CHF and chronic kidney
disease (CKD), also known as ‘cardioerenal interaction’.
Higher NP concentrations have been reported in HF patients
who are also suffering from CKD. The values of NT-proBNP
and glomerular filtration rate (GFR) have been noted to be
inversely and independently related. In the patients with
impaired renal function (GFR <60 ml/min/1.73 m2), a higher
NT-proBNP cut off point of 1200 pg/ml may effectively maxi-
mize sensitivity and specificity of HF diagnosis. So, in the case
of CHF and CKD coincidence, classic NP guided algorithms
may still be appropriate, though cut points need to be read-
justed for renal function. A similar interaction has also been
noted between BNP and GFR.14
6.2. Obesity
Natriuretic peptide values are remarkably lower in obese HF
patients than in non-obese patients. But, the implications of
these lowered concentrations are not yet well understood
(Table 4).15
Table 2 e Trials comparing BNP guided therapy with clinically guided therapy.5
Study Population Intervention Comparison Implication
Beck-da-Silva, 20058 - (LVEF) of 40% or less
- Symptomatic HF
(New York Heart
Association class IIeIV)
for at least 3 months or
previous hospital admission
due to HF
- Age (mean): 65 years.
- < 50% males
- b-blocker dosage up-titrated
according to plasma BNP
levels plus standard care
- b-blocker dosage
up-titrated according
standard care
A trend toward better quality of life was
seen in the BNP group as compared
to the clinically guided group
Jourdain, 2007
STARS-BNP9
- Symptomatic (New York Heart
Association functional class IIeIII)
systolic HF defined by left ventricular
ejection fraction (LVEF) <45%
- Age (mean): 65 years
- <50% females
- Medical therapy was
increasingly used with the
aim of lowering plasma
BNP levels (target <100 pg/ml)
- Each class of therapy modified
according to the judgment of
the investigator
- Medical therapy was
adjusted on the basis
of the physical
examination and usual
para clinical and
biological parameters
BNP guided strategy reduced the
risk of CHF-related death or
hospital stay for CHF
Pfisterer, 2009
TIME-CHF10
- Dyspnea (New York Heart Association
class II with current therapy),
a history of hospitalization for HF
within the last year
- Age (mean): 76 years
- <50% females
- Age subgroups: <75 years; 75 years)
- BNP guided plus symptom
guided medical therapy
- Medical therapy to reduce BNP
levels to 2 times or less than the upper
limit of normal (<400 pg/ml in
patients <75 years and <800 pg/ml
in patients 75 years) and
symptoms to NYHA class of II or less
- Symptom guided
medical therapy
- Medical therapy to
reduce symptoms to
NYHA class of II or less
HF therapy guided by N-terminal
BNP did not improve overall clinical
outcomes or quality of life compared
with symptom guided treatment
HF therapy guided by N-terminal BNP
improved outcomes in patients
aged 60e75 years but not in those
aged 75 years or older
in
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Table 3 e Suggested cut off points for BNP and NT-proBNP use in several situations.12
Cutoff value pg/mL Sensitivity % Specificity % PPV % NPV %
To exclude ADHF
BNP 30e50 97 62 71 96
NT-proBNP 300 99 68 62 99
To identify ADHF
Single cut off point strategy
BNP 100 90 76 79 89
NT-proBNP 900 90 85 76 94
Multiple cut point strategy
BNR, gray zone approach 100 to exclude; 100e400:
gray zone 400 to rule in
450 for age 50 years
90 73 75 90
a a a a
63 91 86 74
NT-proBNP, age-stratified
approach
900 for age 50e75 years 1800
for age 75 years
90 84 88 66
Special situations: renal dysfunction (GFR 60 mL min 1.73 m2)
BNP 200 88 63 83 72
NT-proBNP  1200, all ages
Or
 Age-stratified approach,
above
89 72 74 94
Obesity
BNP 170 for BMI 25 kg/m2 90 77 78 90
110 for 8MI 25e35 kg/m2 90 77 77 90
54 for BMI 35 kg/m2 91 70 70 91
NT-proBNP 900, no adjustment for BMI 87 76 79 90
Age-stratified cut points,
no adjustment for BMI
86 90 85 95
PPV indicates positive predictive value; NPV, negative predictive value; ADHF, acutely decompensated heart failure; BNP, brain natriuretic
peptide; NT-proBNP amino-terminal pro-B-type natriuretic peptide; GFR, glomerular filtration rate; and BMI, body mass index.
a Indicates not applicable.
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Identification of a single cut off point to empirically rule in or
rule out every dyspneic patient with HF is a challenge. The
clinically prevalent algorithms are non-specific and custom-
arily inappropriate as ‘black or white’ diagnoses can’t bemade
based on them. So, to adequately screen patients, two cut off
points are necessary: one to effectively rule out HF in mildly
dyspneic patients and eliminate unneeded hospitalizations,
and another to rule in diagnosis and administer prompt,
appropriate treatment. The ‘gray zone’ between these two cut
off points in which NP concentrations cannot be utilized as
summarily to guide management decisions is the problem
area.4 A gray zone NP value should not be considered entirelyFig. 3 e Brain natriuretic peptide interpretation in the
patients with acute dyspnea without severe renal failure.13uninformative, though it is often not as revealing in HF diag-
nosis. Rather, an intermediate NP value indicates the need for
further clinical examination, and may still aid in patient
prognosis (Table 5).147. Role of BNP testing in emergency
department
Natriuretic protein assays should be used as tools and not as
absolute thresholds for making decisions. A variety ofFig. 4 e N-terminal proBNP interpretation in the patients
with acute dyspnea without severe renal failure.13
Table 4 e Interpretation of NP levels in special
situations.15
Causes of elevated NP levels other than CHF
 LV dysfunction
 Previous heart failure
 Advanced age
 Renal dysfunction
 Acute coronary syndrome
 Pulmonary disease (e,g., acute respiratory distress syndrome,
lung disease with right heart failure)
 Pulmonary embolism
 High output states (e.g., sepsis, cirrhosis, hyperthyroidism)
 Atrial fibrillation
NP levels lower than expected
 Obesity
 Flash pulmonary edema
 Heart failure etiology upstream from LV (e.g., acute mitral
regurgitation, mitral stenosis)
 Cardiac tamponade
 Pericardial constriction
CHF, congestive heart failure; LV, left ventricle; NP, natriuretic
peptide.
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coronary syndrome, pre existing structural heart disease,
right ventricular strain, critical illness, or end-stage renal
failure.16
B-type natriuretic peptide independently predicts high left
ventricular end-diastolic pressure and capillary pulmonary
artery pressure. These pressures correlate well to the NYHA
(New York Heart Association) classification of severity of HF,
and inversely correlate to left ventricular ejection fraction. It
has been shown by some studies that BNP and NT-proBNP can
reliably predict the presence or absence of left ventricular
dysfunction on echocardiography in symptomatic and
asymptomatic HF patients presenting to ED.17
Last decade has seen that BNP has the potential clinical
usefulness for differential diagnosis of dyspnea and for risk
stratification of the patients with CHF. The European Society
of Cardiology Task Force has recommended that the algo-
rithm for HF diagnosis should include an NP assay as the first
step along with electrocardiography (ECG) and chest X-ray.17
The key symptom of CHF and of many other respiratory
diseases, with high associated morbidity and mortality, is
acute dyspnea. It is unfortunate to observe that emergency
physicians’ accuracy in diagnosing CHF is about 60%. In theTable 5 e Diagnostic value of BNP (TriageBNP): Study summa
Logeart22 Dao23
Number of patients 166 250
Mean age 67 ND
Acute CHF (%) 70 39
Male (%) 67 94
Threshold value (pg/ml) 300 100
Sensitivity (%) 88 [NA] 94 [89e97]
Specificity (%) 87 [NA] 94 [89e97]
MA: not available.
Grossly, the higher is the mean age of the population evaluated, the highe
and specificity were given when available [CI].EPIDASA study, conducted on patients older than 65 years
with acute dyspnea, the in-hospital mortality was 16%, with a
highermortality (21%) in the patientswith CHF. The treatment
in ED was inappropriate in 32% patients, and led to a higher
mortality, highlighting the importance of accurate diagnosis
and early accurate treatment in the ED. The initial general
practitioner diagnosis of HF was confirmed in only 34% of the
cases in a prospective study in UK. The clinical indecision at
the ED leads to inappropriate hospitalization and use of
potentially dangerous therapy. The ED physician is uncertain
of the diagnosis (intermediate probability) in one-third of
patients.18
Many studies have evaluated and validated both NP in the
diagnosis of CHF in acute dyspnea. Maisel et al19 performed
the largest studies for BNP and Januzzi et al20 for NT-proBNP.
Following few observations are worth noting from these
studies:
 A BNP concentration >100 pg/mL is a strong independent
predictor of CHF
 Accuracy of BNP (83%) was more than either the NHANES
criteria (67%) or the Framingham criteria (73%), two
commonly used sets of criteria for diagnosing CHF
 The diagnostic accuracy of BNP at a cut off of 100 pg/mlwas
83.4%
 The negative predictive value of this threshold was
particularly high (98%)
The patients who presented in the ED with dyspnea were
included in the PRIDE (ProBNP Investigation of Dyspnea in the
Emergency Department) study. N-terminal proBNP was found
to be highly sensitive and specific for the diagnosis of acute
CHF, with an optimal cut off of 900 pg/ml. The strongest in-
dependent predictor of a final diagnosis of acute CHF was
increased NT-proBNP. Clinical judgment alone for diagnosing
acute CHF was inferior to NT-proBNP testing alone.8. Neurobiomarkers in heart failure:
galectin-3
Galectins are part of a family of lectins which bind b-galac-
tosides. These galectins are expressed in vertebrates aswell as
in invertebrates and even in lower organisms, such as spongeries.21
Lainchbury24 Maisel19 Ray25
205 1586 308
70 64 80
34 47 46
49 56 50
208 100 250
94 [NA] 90 [88e92] 78 [71e84]
70 [NA] 76 [73e79] 90 [84e93]
r is the threshold value of BNP and NT-proBNP; 95% CI for sensitivity
Fig. 5 e Galectin-3 pathway.27
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Presently, 15 members of the galectin family have been
observed in vertebrates. In a seminal paper by Sharma et al26 it
was observed that galectin-3 is increased in decompensatedHF. The authors of the paper opined that galectin-3 may be a
factor that should be considered as a novel target for inter-
vention in HF due to the observation that galectin-3 was
upregulated well before the transition to overt HF.24
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shown that activated macrophages secrete galectin-3 in the
failing or stressed heart. Increased expression levels of
galectin-3 are associated with the tendency to develop
decompensated HF, and in clinical cohorts, increased plasma
galectin-3 levels are linked with worse prognosis. Conse-
quently, galectin-3 may be proclaimed as a novel biomarker,
but it may also be in the pathophysiologic circle of HF (“culprit
biomarker”), and therefore it may also be a target for inter-
vention. The suggested pathways of galectin-3 are displayed
in Fig. 5.26
But, uncertainties are present in proclaiming galectin-3 as
a novel biomarker. Regulation of galectin-3 is unknown at a
transcriptional and translational level in the heart. It has been
demonstrated in mechanistic studies that cardiac fibroblasts
and macrophages are the main sources for galectin-3, and
that the TGF-b/Smad pathway is involved. Regulation is also
governed by inflammatory signals. But, it is confusing as to
which signals govern the production and secretion of galectin-
3. Also, proof-of-principle experiments (e.g., in galectin-3
deficient mice or in pharmacologic studies), to show that
galectin-3 is unequivocally contributing to the onset and
progression of cardiac remodelling are lacking. Again, data on
therapeutic aspects involving galectin-3 expression and
signaling are lacking.26
Available clinical data suggest that plasma and/or serum
galectin-3 is increased in acute and chronic HF. Galectin-3
could be of value to predict prognosis in HF patients.
Galectin-3 in clinical diagnosis and/or decision making is less
convincing as we do not have enough data available to sup-
port the use of the same for this purpose.27
Studies have indicated that standard treatment of HF is
related to lowering of galectin-3 expression and levels; it can
be argued that galectin-3 could be a potential target for ther-
apy. In few small trials, galectin-specific agents have been
tested but these agents have not been evaluated in experi-
mental or clinical HF. Results of studies testing targeted
therapy against galectins should stress for their value in this
devastating disease.279. Multi-marker strategy for complex
patients
Heart failure is a major public health issue. In order to pro-
vide an accurate individualization of HF risk and care, the
approach should include a profile of laboratory data, in
addition to clinical and imaging data. It is clinically impor-
tant to identify the most vulnerable patients, especially
considering that many therapeutic interventions are avail-
able today. Although many novel biomarkers have been
proposed and tested this goal has not been yet reached. The
complexity of the biochemical network involved in the
pathophysiology of HF suggests the ineffectiveness of a sin-
gle marker to reflect all the features of this disease syn-
drome. Combining more markers would help in better
characterization of HF patients and thus create newer op-
tions for treatment and identification of patients that need a
close follow up.The multi-marker approach, considering various
biochemical pathways simultaneously, bases its robustness
on a suitable choice of indices known to be individually
associatedwithHF. Biomarker combination choice is essential
to the performance of the multi-marker strategy.28
A major issue in choosing the biomarker profile is the
proportional increase in financial burden. Hence, for cost
effective evaluation, a biomarker combination has to be used.
Heavily influence results would appear from statistical anal-
ysis and analytical performance of the different elements of
the combination.2810. Conclusion
Use of NT-proBNP or BNP for management of HF is warranted
in view of the increasing prevalence of this serious condition
and the need to consider a broadening spectrum of dysfunc-
tion for treatment. In addition, the complexity of treatment is
increasing with a number of agents demonstrated as effective
through randomized controlled trials. B-type natriuretic pep-
tide and NT-proBNP have comparable clinical utility, and both
help in excluding acute HF. Their use prior to discharge in
hospitalized patients aids risk stratification. In addition,
Galectin-3 may be a factor that should be considered as a
novel target for intervention in HF due to the observation that
galectin-3 was upregulated well before the transition to overt
HF. There will be variable clinical expertise available to di-
agnose and manage the increasing cohort of HF patients with
the passage of time, and an objective indicator to assist
optimal prescription of medications is necessary. At present,
plasma measurements of BNP or NT-proBNP, along with se-
lective use of Galectin-3, constitutes the best candidate for
this function.11. Recommendations for physicians
B-type natriuretic peptide and NT-proBNP are not routinely
used for bedside diagnosis of CHF. This testing is very much
useful in the ED, particularly in patients presenting with
dyspnea when one is uncertain regarding diagnosis of HF.
Sometimes, there could be concurrence of CHF with respira-
tory failure or asthma like illness. In this scenario, serial
measurements of cardiac biomarkers can help to diagnose as
well as plan optimal therapeutic strategies in cases with CHF.
The measurement of cardiac biomarkers also helps to predict
the prognosis and optimal timing for discharging a patient.
B-type natriuretic peptide, in conjunction with Galectin-3,
may be used to identify those patients at higher risk of read-
mission or death thus allowing the physician to better match
the level of care to an individual patient’s needs. These bio-
markers are helpful to physicians, emergency physicians, and
cardiologists in day-to-day practice.Conflicts of interest
All authors have none to declare.
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